Background The pathogenesis of cardiovascular risk in Systemic Erythematosus Lupus (SLE) is the result of a complex interaction between traditional risk factors, disease specific factors and chronic inflammation. To minimize de cardiovascular risk in these patients, doctors should control every risk as possible, to avoid an increase in the mortality and morbidity.
Objectives In order to implement a follow-up protocol in our SLE patients, the authors made a transversal assessment on cardiovascular risk factors, and how they are controlled, or not, in a SLE cohort.
Methods A convenient sample of outpatients with SLE attending our Rheumatology Clinic was recruited. Clinical and laboratorial data were collected using the hospital information records. Statistical analysis was performed using Excel.
Results 60 patients were enrolled (54 women and 6 men), with a mean age of 41,1 years and a mean disease duration of 7,4 years. Mean SLEDAI was 2.86±3.36.
13 patients had smoking habits and 22 patients were overweight, but there were no available data of the weigh or height of 21 patients. 12 patients had a blood pressure superior to 130/80 mmHg. Only 5 patients were insulin resistant, none was diabetic. Mean creatinine was 0,81 mg/dl and albumin 3,9 g/dl. 25 patients had proteinuria >300mg/24 hours. Mean C-reactive protein was 0,73 mg/dl. Concerning cholesterol levels in this SLE patient's cohort: 21 had LDH>100 mg/dl, 12 total cholesterol>200 mg/dl, 7 HDL<40 mg/dl and 5 had triglycerides>150 mg/dl. 7 patients had no lipid profile in the last year.
12 patients were medicated with statins and 28 with angiotensin –converting enzyme inhibitors or angiotensin receptor blockers. The mean dose of corticosteroid was 5.6 mg pd.
In this SLE cohort, there were 8 thrombotic vascular events but 5 of these patients had also antiphospholipid syndrome.
Conclusions The results reinforce the importance of a protocolled follow-up that could avoid the lack of some important clinical and laboratorial data and a better/more efficient control of co-morbidities in SLE patients.
Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupuserythematosus. Am J Epidemiol. 2012 Oct 15;176(8):708-19
Disclosure of Interest None declared